CohBar ^Company

CohBar is a clinical stage biotechnology company focused on the research and development of mitochondria based therapeutics, an emerging class of drugs for the treatment of chronic and age-related diseases. Our company is a first mover and leader in exploring the mitochondrial genome for therapeutically relevant peptides that have the potential to be developed into transformative and commercially successful drugs. These peptides have been conserved by evolutionary biology due to their important roles in sensing and regulating critical biological functions, far beyond the energy production most frequently associated with mitochondria. Our team has discovered more than 100 mitochondrial derived peptides (MDPs) and generated over 1,000 analogs.